HK1258611A1 - 腹水的治疗 - Google Patents

腹水的治疗 Download PDF

Info

Publication number
HK1258611A1
HK1258611A1 HK19100970.3A HK19100970A HK1258611A1 HK 1258611 A1 HK1258611 A1 HK 1258611A1 HK 19100970 A HK19100970 A HK 19100970A HK 1258611 A1 HK1258611 A1 HK 1258611A1
Authority
HK
Hong Kong
Prior art keywords
ascites
continuous infusion
treatment
patients
terlipressin
Prior art date
Application number
HK19100970.3A
Other languages
English (en)
Chinese (zh)
Inventor
Paolo Angeli
Penelope MARKHAM
Jonathan Adams
Original Assignee
Biovie Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57609113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1258611(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biovie Inc. filed Critical Biovie Inc.
Publication of HK1258611A1 publication Critical patent/HK1258611A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
HK19100970.3A 2015-06-30 2016-06-30 腹水的治疗 HK1258611A1 (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562186638P 2015-06-30 2015-06-30
US62/186,638 2015-06-30
US201562267510P 2015-12-15 2015-12-15
US62/267,510 2015-12-15
US201662321558P 2016-04-12 2016-04-12
US62/321,558 2016-04-12
PCT/US2016/040284 WO2017004317A1 (en) 2015-06-30 2016-06-30 Treatment of ascites

Publications (1)

Publication Number Publication Date
HK1258611A1 true HK1258611A1 (zh) 2019-11-15

Family

ID=57609113

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19100970.3A HK1258611A1 (zh) 2015-06-30 2016-06-30 腹水的治疗

Country Status (7)

Country Link
US (6) US9655945B2 (https=)
EP (2) EP3347032B1 (https=)
JP (6) JP2017014206A (https=)
CN (2) CN106999539A (https=)
ES (1) ES2971959T3 (https=)
HK (1) HK1258611A1 (https=)
WO (1) WO2017004317A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102176900B (zh) 2008-09-17 2017-09-26 克艾思马有限公司 药物组合物和相关的给药方法
HUE058066T2 (hu) 2014-10-24 2022-06-28 Mallinckrodt Pharmaceuticals Ireland Ltd Terlipressin 1-es típusú hepatorenális szindróma kezelésére
HUE071943T2 (hu) 2015-02-03 2025-10-28 Amryt Endo Inc Akromegália kezelése oktreotid orális alkalmazásával
JP2017014206A (ja) * 2015-06-30 2017-01-19 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療
CA3037581A1 (en) 2016-10-21 2018-04-26 Chiasma, Inc. Terlipressin compositions and their methods of use
CN112704727B (zh) * 2021-01-12 2023-05-16 重庆医科大学附属第二医院 特利加压素在制备动力性肠梗阻药物中的应用
CN113077888A (zh) * 2021-03-30 2021-07-06 福州宜星大数据产业投资有限公司 自动化meld评分方法、终端及存储介质
JP2025505010A (ja) * 2022-02-03 2025-02-19 バイオビー インコーポレーテッド テルリプレシンを用いた疾患の治療方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188443A1 (en) * 2000-09-15 2002-03-20 Ferring BV Improved protocol for paracentesis
HUE027174T2 (en) * 2006-02-13 2016-10-28 Ferring Bv Use of peptide agonists of the vasopressin receptor
WO2009037586A2 (en) * 2007-08-14 2009-03-26 Ferring B.V. Use of peptidic vasopressin receptor agonists
EP2203172A2 (en) * 2007-09-28 2010-07-07 Ferring B.V. Use of v2 receptor antagonists in combination with vasopressinergic agonists
EP2214709A4 (en) * 2007-11-08 2011-05-11 Univ Utah Res Found USE OF ANGIOGENESIS ANTAGONISTS IN DISEASES WITH ANOMAL VENEER PREPARATION
US8815232B2 (en) 2008-08-26 2014-08-26 Kyon Biotech Ag Compositions and methods for treating cancer
US9464284B2 (en) * 2009-03-09 2016-10-11 Bioatla, Llc Mirac proteins
EA201691430A1 (ru) * 2009-06-08 2017-02-28 ЮСиЭл БИЗНЕС ПиЭлСи Лечение портальной гипертензии и восстановление функции печени с помощью l-орнитинфенилацетата
WO2012009545A1 (en) * 2010-07-14 2012-01-19 Cumberland Emerging Technologies, Inc Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-a2 receptor antagonists
WO2013106072A1 (en) * 2012-01-10 2013-07-18 Sorbent Therapeutics, Inc. Compositions comprising crosslinked cation-binding polymers and uses thereof
JO3109B1 (ar) 2012-05-10 2017-09-20 Ferring Bv منبهات لمستقبلات v1a
CN102731625B (zh) * 2012-06-27 2014-10-15 深圳翰宇药业股份有限公司 一种纯化特利加压素的方法
WO2014075082A1 (en) * 2012-11-12 2014-05-15 Gregory Thomas Everson Disease severity index for assessment of chronic liver disease and method for diagnosis of three distinct subtypes of primary sclerosing cholangitis
CN105592855A (zh) * 2013-04-26 2016-05-18 拉卓拉药物公司 用于治疗肾衰竭的组合物和方法
US20150056194A1 (en) 2013-08-21 2015-02-26 Georgia Regents Research Institute, Inc. Modified green tea polyphenols and methods thereof for treating liver disease
JP2017014206A (ja) * 2015-06-30 2017-01-19 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療

Also Published As

Publication number Publication date
EP3347032A1 (en) 2018-07-18
JP2023160839A (ja) 2023-11-02
US20170000844A1 (en) 2017-01-05
EP3347032B1 (en) 2023-11-29
US20250312410A1 (en) 2025-10-09
ES2971959T3 (es) 2024-06-10
JP2025143324A (ja) 2025-10-01
CN120324576A (zh) 2025-07-18
WO2017004317A1 (en) 2017-01-05
JP2017014206A (ja) 2017-01-19
US20230146264A1 (en) 2023-05-11
JP2022136104A (ja) 2022-09-15
US20240165193A1 (en) 2024-05-23
US20180000887A1 (en) 2018-01-04
US20190365848A1 (en) 2019-12-05
JP2018172440A (ja) 2018-11-08
EP4338795A3 (en) 2024-08-28
US9655945B2 (en) 2017-05-23
JP2020172520A (ja) 2020-10-22
CN106999539A (zh) 2017-08-01
US11364277B2 (en) 2022-06-21
EP4338795A2 (en) 2024-03-20
EP3347032A4 (en) 2019-06-19

Similar Documents

Publication Publication Date Title
HK1258611A1 (zh) 腹水的治疗
CA187580S (en) Administration set for infusion pump
IL263670A (en) Assemblies and methods for infusion pump system delivery kits
SG11201910969VA (en) Cannula for intravascular blood pump
WO2012115772A3 (en) Therapy for kidney disease and/or heart failure
HK1226309A1 (zh) 包含粘度降低剂的液体蛋白质制剂
EP4570314A3 (en) Sacubitril-valsartan dosage regimen for treating chronic systolic heart failure
EA201891946A1 (ru) Коагонисты глюкагона и glp-1 для лечения ожирения
MX2018004834A (es) Metodos para tratar dolor usando dimeros de acetominofeno farmaceuticamente activos enlazados a traves de grupos hidroxilo fenolicos.
CY1119957T1 (el) Θεραπεια νοσηματων με τη χρηση ανοχογονου φαρμακευτικου παρασκευασματος
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
IL275282A (en) Infusion pump systems and methods for administration kits
MD20150120A2 (ro) Tratamentul bolilor neurodegenerative şi miopatice de agregare proteică prin administrarea parenterală a trehalozei
MX391926B (es) Uso de medicamentos con propiedades neuroprotectoras para prevenir o reducir el riesgo del daño por isquemia-reperfusion en un sujeto.
EP3256133A4 (en) Intravenous infusion dosage form
PH12017501290A1 (en) Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide
BR112017000898A2 (pt) oritavancina de alta pureza e método de produção da mesma
MX2016011881A (es) Medicamento de peptido en polvo seco.
HK1254855A1 (zh) 在手术期间给患者静脉内施用瓜氨酸
EP3174574A4 (en) Medicament infusion system and pump assembly for use therein
PH12016501347A1 (en) Filters for infusion sets
MX2020007270A (es) Formulacion parenteral que comprende siponimod.
EP3225267A4 (en) Drug administration mechanism, method for using drug administration mechanism, and pump unit for drug administration mechanism
SG10201809418VA (en) New administration routes of insulin, insulin analogs or derivatives of insulin
WO2014149998A8 (en) Systemic administration of androgen in treating dry eye syndrome